The European Medicines Agency will decide this week whether to recommend EU-wide approval for a dozen new drugs, including BeiGene’s Brukinsa (zanubrutinib) for treating Waldenström’s macroglobulinemia, and Apellis Pharmaceuticals’ pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria.
Brukinsa and pegcetacoplan are among five orphan medicines that are listed on the agenda of the latest monthly meeting...








